QuidelOrtho upped to neutral at UBS on current valuation, diagnostics survey

Oct. 14, 2022 1:53 PM ETQuidelOrtho Corporation (QDEL)By: Jonathan Block, SA News Editor

Markets Open As Volatility Continues

Michael M. Santiago

  • UBS upgraded QuidelOrtho (NASDAQ:QDEL) to neutral from sell as the company's Q3 2022 earnings pre-announcement had revenues come in ahead of the firm's forecast.
  • The firm has an $86 price target (~15% upside based on Thursday's close).

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.